Law firms lay down swords in Mesoblast shareholder class actions

Article 2022-08-24 1:54 pm By Cat Fredenburgh | Melbourne

Please login to bookmark

Two law firms that filed competing class actions against regenerative medicine company Mesoblast for allegedly misleading shareholders about its Remestemcel-L treatment for COVID-19 complications have agreed to join forces and sidestep a beauty parade.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au